ArticleOpen life sciences2026
Low-molecular-weight metabolites from lactic acid bacteria suppress cervical cancer progression by inhibiting EMT via the Wnt/β-catenin pathway.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to explore the effects of Lactic Acid Bacteria (LAB) supernatant on the epithelial-mesenchymal transition (EMT) of the cervical cancer cell lines HeLa, SiHa, and Hcerepic. We assessed the effect of LAB culture and its supernatant on the proliferation of these cells using the Cell Counting Kit-8 (CCK-8). Scratch assays were performed to evaluate cell migration inhibition. The supernatant was fractionated into >3 kDa and ≤3 kDa components to compare the antiproliferative and antimigratory properties of two fractions. Further, we analyzed the effect of ≤3 kDa supernatant on EMT markers and the Wnt/β-catenin pathway, as well as its effect under LiCl-induced Wnt/β-catenin activation. Grayscale values were obtained using Clinx Chemi Analysis software (ChemiScope 6000, Shanghai, China). LAB and its supernatant significantly inhibited cell proliferation, and the supernatant was more effective. The scratch assay indicated that the LAB supernatant markedly suppressed cell migration. The ≤3 kDa fraction exhibited stronger antiproliferative and antimigratory effects than the >3 kDa fraction. Mechanistically, the ≤3 kDa supernatant reversed EMT by upregulating E-cadherin and downregulating N-cadherin, Vimentin, and Snail. This fraction also inhibited the Wnt/β-catenin pathway, as evidenced by decreased Wnt1, SMAD4, and β-catenin levels, as well as suppressed Gsk-3β phosphorylation. Notably, the ≤3 kDa supernatant maintained its inhibitory effects on proliferation, migration, and EMT even when the Wnt/β-catenin pathway was activated by LiCl. In conclusion, LAB-derived low-molecular-weight metabolites hold therapeutic potential for cervical cancer. The ≤3 kDa supernatant inhibits cancer progression and metastasis by targeting the Wnt/β-catenin pathway and reversing EMT, representing a promising therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.